Last-Resort access: alpelisib opens for patients with no other options
NCT ID NCT04085653
First seen Dec 10, 2025 · Last updated May 19, 2026 · Updated 20 times
Summary
This program provides access to the drug alpelisib (BYL719) for patients with serious conditions like PIK3CA-related overgrowth spectrum (PROS) or breast cancer who have no other treatment options and cannot join a clinical trial. It is not a standard study but a managed access program where doctors can request the drug for individual patients. The goal is to offer potential benefit when no comparable therapy exists.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.